- Home
- ARHS vs ANAB Comparison
ARHS vs ANAB Comparison
Compare ARHS & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARHS | ANAB |
|---|---|---|
| Founded | 1986 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ARHS | ANAB |
|---|---|---|
| Price | $10.61 | $46.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 12 |
| Target Price | $12.00 | ★ $60.18 |
| AVG Volume (30 Days) | ★ 1.2M | 532.7K |
| Earning Date | 02-25-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $1,361,388,000.00 | $169,467,000.00 |
| Revenue This Year | $9.59 | $135.51 |
| Revenue Next Year | $6.46 | N/A |
| P/E Ratio | $19.58 | ★ N/A |
| Revenue Growth | 7.36 | ★ 196.42 |
| 52 Week Low | $6.61 | $12.21 |
| 52 Week High | $13.02 | $52.47 |
Technical Indicators
Market Signals| Indicator | ARHS | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 45.71 | 51.99 |
| Support Level | $10.02 | $44.25 |
| Resistance Level | $11.18 | $50.50 |
| Average True Range (ATR) | 0.50 | 3.06 |
| MACD | -0.12 | -0.32 |
| Stochastic Oscillator | 37.91 | 54.24 |
Price Performance
Historical ComparisonAbout ARHS Arhaus Inc.
Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in several categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and e-commerce sales channels.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).